Symmetrix Biotech

Symmetrix Biotech is a biotechnology company and a subsidiary of Nostrum Pharmaceuticals, focused on the development of novel biopharmaceutical therapeutic proteins and small molecules. The company's lead candidate, SMRX-11 (Clot Specific Streptokinase), is a recombinant protein designed to treat acute myocardial infarction by targeting plasminogen only in the presence of a blood clot, thereby reducing bleeding risks. Symmetrix Biotech operates through a significant public-private partnership with the CSIR-Institute of Microbial Technology (IMTECH) in India. In addition to cardiovascular therapies, the company is developing Caerulomycin, a small molecule with potential applications in immunosuppression for autoimmune conditions. Headquartered in Mumbai, Symmetrix Biotech leverages its parent company's expertise in pharmaceutical development to advance its clinical pipeline.